{"pmid":32368792,"title":"Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2.","text":["Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2.","As of April 9, 2020, a novel coronavirus (SARS-CoV-2) had caused 89,931 deaths and 1,503,900 confirmed cases worldwide, which indicates an increasingly severe and uncontrollable situation. Initially, little was known about the virus. As research continues, we have learned the genome structure, epidemiological and clinical characteristics and pathogenic mechanisms of SARS-CoV-2. Based on these discoveries, identifying potential targets involved in the processes of virus pathogenesis is urgently needed, and discovering or developing promising drugs based on potential targets is the most pressing need. Therefore, we summarize the potential therapeutic targets involved in virus pathogenesis and discuss the advancements, possibilities and significance of promising drugs based on these targets for treating SARS-CoV-2. This review will facilitate the identification of potential targets and provide promising clues for drug development that can be translated into clinical applications for combating SARS-CoV-2.","Br J Pharmacol","Zhou, Hong","Fang, Yan","Xu, Tao","Ni, Wei-Jian","Shen, Ai-Zong","Meng, Xiao-Ming","32368792"],"abstract":["As of April 9, 2020, a novel coronavirus (SARS-CoV-2) had caused 89,931 deaths and 1,503,900 confirmed cases worldwide, which indicates an increasingly severe and uncontrollable situation. Initially, little was known about the virus. As research continues, we have learned the genome structure, epidemiological and clinical characteristics and pathogenic mechanisms of SARS-CoV-2. Based on these discoveries, identifying potential targets involved in the processes of virus pathogenesis is urgently needed, and discovering or developing promising drugs based on potential targets is the most pressing need. Therefore, we summarize the potential therapeutic targets involved in virus pathogenesis and discuss the advancements, possibilities and significance of promising drugs based on these targets for treating SARS-CoV-2. This review will facilitate the identification of potential targets and provide promising clues for drug development that can be translated into clinical applications for combating SARS-CoV-2."],"journal":"Br J Pharmacol","authors":["Zhou, Hong","Fang, Yan","Xu, Tao","Ni, Wei-Jian","Shen, Ai-Zong","Meng, Xiao-Ming"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368792","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/bph.15092","keywords":["sars-cov-2","epidemiological and clinical characteristics","outbreak","potential targets","promising drugs"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496218169344,"score":9.490897,"similar":[{"pmid":32442720,"title":"A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).","text":["A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).","The epidemic of pneumonia (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has been listed as a public health emergency of international concern by the World Health Organization (WHO), and its harm degree is defined as a global \"pandemic\". At present, the efforts of various countries focus on the rapid diagnosis and isolation of patients, as well as to find a treatment that can combat the most serious impact of the disease. The number of reported COVID-19 virus infections is still increasing. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses, but there is an urgent need for in-depth research on emerging human infectious coronaviruses. Clarification transmission routes and pathogenic mechanisms, and identification of potential drug treatment targets will promote the development of effective prevention and treatment measures. In the absence of confirmed effective treatments, due to public health emergencies, it is essential to study the possible effects of existing approved antivirals drugs or Chinese herbal medicines for SARS-CoV-2. This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19. Meanwhile, this review also focus on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat COVID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID-19.","Pharmacol Res","Huang, Fangfang","Li, Ying","Leung, Elaine Lai-Han","Liu, Xiaohua","Liu, Kaifeng","Wang, Qu","Lan, Yongqi","Li, Xiaoling","Yu, Haibing","Cu, Liao","Luo, Hui","Luo, Lianxiang","32442720"],"abstract":["The epidemic of pneumonia (COVID-19) caused by novel coronavirus (SARS-CoV-2) infection has been listed as a public health emergency of international concern by the World Health Organization (WHO), and its harm degree is defined as a global \"pandemic\". At present, the efforts of various countries focus on the rapid diagnosis and isolation of patients, as well as to find a treatment that can combat the most serious impact of the disease. The number of reported COVID-19 virus infections is still increasing. Unfortunately, no drugs or vaccines have been approved for the treatment of human coronaviruses, but there is an urgent need for in-depth research on emerging human infectious coronaviruses. Clarification transmission routes and pathogenic mechanisms, and identification of potential drug treatment targets will promote the development of effective prevention and treatment measures. In the absence of confirmed effective treatments, due to public health emergencies, it is essential to study the possible effects of existing approved antivirals drugs or Chinese herbal medicines for SARS-CoV-2. This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19. Meanwhile, this review also focus on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat COVID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID-19."],"journal":"Pharmacol Res","authors":["Huang, Fangfang","Li, Ying","Leung, Elaine Lai-Han","Liu, Xiaohua","Liu, Kaifeng","Wang, Qu","Lan, Yongqi","Li, Xiaoling","Yu, Haibing","Cu, Liao","Luo, Hui","Luo, Lianxiang"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442720","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.phrs.2020.104929","keywords":["covid-19","chinese herbal medicines","pneumonia","sars-cov-2","therapeutic agents","treatment"],"locations":["Chinese","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667535119519318016,"score":229.5422},{"pmid":32239142,"pmcid":"PMC7184403","title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.","text":["Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus.","MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19.","Bioinformatics","Liu, Sen","Zheng, Qiang","Wang, Zhiying","32239142"],"abstract":["MOTIVATION: Since December 2019, the newly identified coronavirus SARS-CoV-2 has caused a massive health crisis worldwide and resulted in over 70,000 COVID-19 infections so far. Clinical drugs targeting SARS-CoV-2 are urgently needed to decrease the high fatality rate of confirmed COVID-19 patients. Traditional de novo drug discovery needs more than 10 years, so drug repurposing seems the best option currently to find potential drugs for treating COVID-19. RESULTS: Compared with traditional non-covalent drugs, covalent drugs have attracted escalating attention recent years due to their advantages in potential specificity upon careful design, efficiency, and patient burden. We recently developed a computational protocol named as SCAR for discovering covalent drugs. In this work, we used the SCAR protocol to identify possible covalent drugs (approved or clinically tested) targeting the main protease (3CLpro) of SARS-CoV-2. We identified 11 potential hits, among which at least 6 hits were exclusively enriched by the SCAR protocol. Since the preclinical or clinical information of these identified drugs is already available, they might be ready for being clinically tested in the treatment of COVID-19."],"journal":"Bioinformatics","authors":["Liu, Sen","Zheng, Qiang","Wang, Zhiying"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32239142","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1093/bioinformatics/btaa224","topics":["Treatment"],"weight":1,"_version_":1666138490266451969,"score":206.07513},{"pmid":32234466,"pmcid":"PMC7139247","title":"Coronavirus disease 2019 (COVID-19): current status and future perspectives.","text":["Coronavirus disease 2019 (COVID-19): current status and future perspectives.","Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics.","Int J Antimicrob Agents","Li, Heng","Liu, Shang-Ming","Yu, Xiao-Hua","Tang, Shi-Lin","Tang, Chao-Ke","32234466"],"abstract":["Coronavirus disease 2019 (COVID-19) originated in the city of Wuhan, Hubei Province, Central China, and has spread quickly to 72 countries to date. COVID-19 is caused by a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [previously provisionally known as 2019 novel coronavirus (2019-nCoV)]. At present, the newly identified SARS-CoV-2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged SARS-CoV-2 is urgently needed to elucidate the pathogenic mechanisms and epidemiological characteristics and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV-2 and the characteristics of COVID-19, such as the aetiology, pathogenesis and epidemiological characteristics."],"journal":"Int J Antimicrob Agents","authors":["Li, Heng","Liu, Shang-Ming","Yu, Xiao-Hua","Tang, Shi-Lin","Tang, Chao-Ke"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234466","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105951","keywords":["2019-ncov","covid-19","coronavirus","pneumonia","sars-cov-2"],"locations":["Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1666138490238140419,"score":199.76573},{"pmid":32292689,"pmcid":"PMC7102550","title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","text":["Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.","SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.","Acta Pharm Sin B","Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua","32292689"],"abstract":["SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further in vitro and in vivo studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections."],"journal":"Acta Pharm Sin B","authors":["Wu, Canrong","Liu, Yang","Yang, Yueying","Zhang, Peng","Zhong, Wu","Wang, Yali","Wang, Qiqi","Xu, Yang","Li, Mingxue","Li, Xingzhou","Zheng, Mengzhu","Chen, Lixia","Li, Hua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292689","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.apsb.2020.02.008","keywords":["3clpro, 3-chymotrypsin-like protease","drug repurposing","e, envelope","homology modeling","m, membrane protein","molecular docking","n, nucleocapsid protein","nsp, non-structure protein","orf, open reading frame","pdb, protein data bank","rdrp, rna-dependence rna polymerase","remdesivir","s, spike","sars-cov-2","sud, sars unique domain","ub, ubiquitin-like domain"],"topics":["Treatment"],"weight":1,"_version_":1666138494492213249,"score":197.96492},{"pmid":32419926,"pmcid":"PMC7202090","title":"Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.","text":["Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target.","A novel coronavirus recently identified in Wuhan, China (SARS-CoV-2) has expanded the number of highly pathogenic coronaviruses affecting humans. The SARS-CoV-2 represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging SARS-CoV-2 is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Actin protein was also suggested as a host factor that participates in cell entry and pathogenesis of SARS-CoV-2; therefore, drugs modulating biological activity of this protein (e.g. ibuprofen) were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2, and that domain 288-330 of S1 protein from the SARS-CoV-2 represents promising therapeutic and/or vaccine target.","F1000Res","Veljkovic, Veljko","Vergara-Alert, Julia","Segales, Joaquim","Paessler, Slobodan","32419926"],"abstract":["A novel coronavirus recently identified in Wuhan, China (SARS-CoV-2) has expanded the number of highly pathogenic coronaviruses affecting humans. The SARS-CoV-2 represents a potential epidemic or pandemic threat, which requires a quick response for preparedness against this infection. The present report uses the informational spectrum methodology to identify the possible origin and natural host of the new virus, as well as putative therapeutic and vaccine targets. The performed in silico analysis indicates that the newly emerging SARS-CoV-2 is closely related to severe acute respiratory syndrome (SARS)-CoV and, to a lesser degree, Middle East respiratory syndrome (MERS)-CoV. Moreover, the well-known SARS-CoV receptor (ACE2) might be a putative receptor for the novel virus as well. Actin protein was also suggested as a host factor that participates in cell entry and pathogenesis of SARS-CoV-2; therefore, drugs modulating biological activity of this protein (e.g. ibuprofen) were suggested as potential candidates for treatment of this viral infection. Additional results indicated that civets and poultry are potential candidates for the natural reservoir of the SARS-CoV-2, and that domain 288-330 of S1 protein from the SARS-CoV-2 represents promising therapeutic and/or vaccine target."],"journal":"F1000Res","authors":["Veljkovic, Veljko","Vergara-Alert, Julia","Segales, Joaquim","Paessler, Slobodan"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32419926","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.12688/f1000research.22149.3","keywords":["2019-ncov","mers","sars","wuhan coronavirus"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288181788673,"score":194.90643}]}